Aegis Capital initiated coverage on Navidea Biopharmaceuticals NAVB with a Hold rating and a $3.00 price target.
Aegis Capital noted, "While we are relatively optimistic regarding Navidea's near-term ability to obtain regulatory approval for its most advanced product candidate, Lymphoseek, we remain cautious about the agent's commercial prospects. … We believe that Lymphoseek could be a successful product, with peak sales potential of $450mm in the U.S. alone and in excess of $700mm worldwide. However, in the absence of regulatory approval in the U.S., we would advise investors to wait watchfully."
Navidea Biopharmaceuticals closed at $2.97 on Friday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in